Search Results

Aspen Neuroscience, Inc. has received a CLIN2 grant award of $8 million from the California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, to support clinical research aimed at treating Parkinson’s disease (PD).

Lineage Cell Therapeutics, Inc. today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM).

Senti Biosciences, Inc., a biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, announced that the California Institute for Regenerative Medicines has awarded an $8 million grant to Senti Bio.

Andelyn Biosciences, Inc. has been selected to manufacture adeno-associated vectors therapies using its suspension AAV Curator™ Platform under the California Institute for Regenerative Medicine Accelerating Medicines Partnership Bespoke Gene Therapy Consortium.

Allogene Therapeutics, Inc. announced that it has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the clinical development of ALLO-316, an AlloCAR T™ investigational product targeting CD70 in development for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Forge Biologics (Forge), a leading manufacturer of genetic medicines, announced today that it has joined the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program to help advance the manufacturing of adeno-associated adenovirus (AAV) gene therapy programs from the state of California.

Avid Bioservices, Inc. announced a new partnership with the California Institute for Regenerative Medicine Industry Resource Partner Program.

Funding will advance development of Rejuvenate’s one-time gene therapy RJB-0402 for the treatment of desmoplakin gene variant arrhythmogenic cardiomyopathy

Siren Biotechnology announced that the California Institute for Regenerative Medicine has awarded the company a $4M translational research grant to support the development of novel AAV immuno-gene therapies for cancer.